Aspirin + rivaroxaban
Aspirin + rivaroxaban has been studied in 1 paper since 2026: none in people yet, 1 review; 1 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 22, 2026: “Polyvascular Atherosclerotic Disease Across Contemporary ESC Guidelines: Key Updates, Clinical Gaps, and Future Perspectives”.
1 new paper in 30 daysSee all 10 papers on aspirin + rivaroxaban
Latest
3 papers in 12 monthsWorld Journal of Cardiology
Subclinical atrial fibrillation: Implications of recent trials for guideline updates?
ReviewAtrial fibrillation
The New England Journal of Medicine
Peripheral Artery Disease in the Legs
The Canadian Journal of Cardiology
Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial
Randomized trial in peopleCardiovascular disease
The Canadian Journal of Cardiology
Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease
Systematic reviewIndustry & policy
Journal of Stroke and Cerebrovascular Diseases
Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale
Study of 7,213 peopleStroke
Research Square
Safety of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) randomized controlled trials
Preprint: meta-analysis of randomized trialsDirect oral anticoagulants
International Journal of Cardiology
Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
Computational studyInterventions